Drug Discovery Featured Articles & Applications

  1. SARS-CoV-2: Massey Univ. Profs Develop Method To Quickly Sequence Genome 8/13/2021

    It was a matter of time before the world saw variants emerge that increased the transmission rate of COVID-19. A research team led by two of these authors at Massey University have developed a new next-generation sequencing method for the ultrafast sequencing of the SARS-CoV-2 genome, which cuts the sequencing time by more than half.

  2. Decoding The Immune Synapse To Create Novel Immunotherapies 8/2/2021

    The potential of T cell therapies to be curative by harnessing our own immune repertoire has exciting implications for cancer and many other immune-mediated disorders.

  3. New Discoveries For Hemophilia A 7/30/2021

    The Mayo Clinic describes Hemophilia A as a rare, inherited disorder in which the blood doesn't clot normally, because it lacks sufficient blood-clotting proteins (clotting factors). People with hemophilia may bleed for a longer time after an injury than they would if their blood clotted normally. Hemophilia A, also known as classical hemophilia, is a genetic bleeding disorder caused by insufficient levels of a blood protein called factor VIII, which is a clotting factor.

  4. These Are The Top Priorities & Challenges For New CDER Director Patrizia Cavazzoni, M.D. 7/30/2021

    Recently appointed to the permanent CDER director role, Dr. Cavazzoni’s appointment was not unexpected, as she was recruited to join the FDA in 2018 from a senior industry role and served as acting CDER director at the start of the agency’s pandemic response. Her experience suggests she will continue to evolve – rather than revolutionize – FDA’s drug review policies.

  5. 10 Critical Validation Parameters For Microbiological Experiments 7/26/2021

    In studying a microbiological method, different validation parameters require assessment. These are variables or factors that can be controlled, changed, or measured in the experiment. This article outlines the key parameters to consider.

  6. Emerging Biopharma: Your Next 2 Geographic Markets To Tackle After The US 7/7/2021

    While the majority of the world’s drug development and innovation are underwritten by the United States, emerging drug developers should not overlook these two major regions of the world that represent volume, profit, ingenuity, and growth. 

  7. Cell & Gene Therapies For Parkinson’s Disease 7/6/2021

    Emile Nuwaysir, President and CEO of BlueRock Therapeutics explains the recruitment process for the trial, the trial’s primary objective, and more.

  8. Biologics Discovery: Picking Winners & Losers 6/18/2021

    Glympse Bio is developing bio-engineered, in-vivo diagnostic technologies that could offer biologics developers earlier insight into target engagement and therapeutic response. That spells big implications on translational research, speed to clinic, and time to market.

  9. Five Maxims For Outsourcing Success 6/8/2021

    "Outsourcing is really about positioning your CDMO to your competitive advantage," says Lis Wyman of Acceleron Pharma. That might just be the "maximum maxim" for outsourcing strategy. But Wyman has four more to offer, all enlightening to your craft of drug development and manufacturing.

  10. The Potential And Future Of Cell Therapy 4/22/2021

    While the field has made laudable progress in developing novel biomolecules that can be used to control cell function (e.g. mRNA, DNA, CRISPR, siRNA, proteins, peptides, etc.), very little progress has been made on reliably delivering these materials to a cell and enabling robust engineering of cell function without significantly impairing cell health.